Insider Transactions in Q1 2024 at Intellia Therapeutics, Inc. (NTLA)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2024
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
605
-0.84%
|
$19,360
$32.99 P/Share
|
|
Mar 04
2024
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,297
-2.74%
|
$73,504
$32.99 P/Share
|
|
Mar 01
2024
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,628
+29.26%
|
-
|
|
Mar 01
2024
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,701
+29.37%
|
-
|
|
Mar 01
2024
|
John M Leonard President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
113,586
+10.58%
|
-
|
|
Mar 01
2024
|
Eliana Clark EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,230
+30.23%
|
-
|
|
Mar 01
2024
|
Derek Hicks EVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,393
+30.69%
|
-
|
|
Mar 01
2024
|
James Basta EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
32,394
+27.86%
|
-
|
|
Mar 01
2024
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,966
+31.68%
|
-
|
|
Jan 08
2024
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,275
-2.49%
|
$65,975
$29.02 P/Share
|
|
Jan 03
2024
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,532
-10.69%
|
$160,428
$29.46 P/Share
|
|
Jan 03
2024
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,843
-9.7%
|
$169,447
$29.46 P/Share
|
|
Jan 03
2024
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
19,223
-2.22%
|
$557,467
$29.46 P/Share
|
|
Jan 03
2024
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
4,608
-5.1%
|
$133,632
$29.79 P/Share
|
|
Jan 03
2024
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
3,805
-6.88%
|
$110,345
$29.46 P/Share
|
|
Jan 03
2024
|
Derek Hicks EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,877
-9.49%
|
$112,433
$29.46 P/Share
|
|
Jan 03
2024
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,365
-11.68%
|
$155,585
$29.46 P/Share
|
|
Jan 01
2024
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+6.34%
|
-
|
|
Jan 01
2024
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,848
+0.9%
|
-
|
|
Jan 01
2024
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,187
+5.03%
|
-
|
|
Jan 01
2024
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,062
+6.25%
|
-
|